Recruiting

Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer

# NCT04262856 Trial phase: 2 Study type: immunotherapy, targeted

Study Start Date

May, 2020

Scientific Title

A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination With AB122, and AB154 in Combination With AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer

Summary

This randomized phase 2 open-label study will evaluate the safety and efficacy of zimberelimab (AB122) monotherapy, domvanalimab (AB154) in combination with zimberelimab, and domvanalimab in combination with zimberelimab and etrumadenant (AB928) in front-line, PD-L1 positive, locally advanced or metastatic non-small cell lung cancer.

- Male or female participants; age ≥ 18 years - Histologically confirmed squamous or nonsquamous, PD-L1 positive, NSCLC that is locally advanced or metastatic without sensitizing epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutation expression - Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 - Must have at least 1 measurable lesion per RECIST v1.1 - Adequate organ and marrow function

Study Design

Primary purpose: Treatment , Allocation: Randomized , Intervention model: Parallel Assignment , Masking: None (Open Label),

Conditions

Lung Cancer, Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer

Other Study ID Numbers

AB154CSP0002

Locations

Please to see your matching score and connect to trial sponsor